223 completed, 99 recruiting, 83 active not recruiting, 69 unknown. 365 Phase 2, 183 Phase 1, 91 Phase 3, 13 Not applicable, 6 Early Phase 1.
Follow Taxes: new trials by email Literature Review of Taxes trials Research Report on Taxes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Biospecimen Collection, Computed Tomography, Futibatinib - Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 1 | Not yet recruiting | Northwestern University | 18 | 2027-09-09 | 2026-10-20 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Repurposing Mefloquine for Pancreatic Cancer Treatment Mefloquine, Modified FOLFIRINOX, gemcitabine and nab paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | University of Florida | 36 | 2026-11-01 | 2026-10-15 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 940 | 2026-09-22 | 2026-10-20 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) - Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Withdrawn | ImmunityBio, Inc. | 2026-09-01 | 2026-08-28 | |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma Camrelizumab, Esophagectomy, Sample - Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 45 | 2026-08-17 | 2026-10-02 |
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer ANO31905, Nanoparticle Albumin-Bound Paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Anova Innovation Limited | 84 | 2026-08-01 | 2026-07-27 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC Adebrelimab, Nab paclitaxel, Carboplatin - Esophageal Cancer | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-07-31 | 2026-07-29 |
| Taxation Online Experimental Supermarket Taxation, Subsidies - Nutrition, Food Purchasing Intention | Not applicable | Recruiting | University of Paris 13 | 2239 | 2026-06-15 | 2026-06-30 |
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Nab paclitaxel / gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 110 | 2026-06-01 | 2026-06-11 |
| Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC Retlirafusp alfa, Nab paclitaxel, Cisplatin for injection - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Tang-Du Hospital | 33 | 2026-05-30 | 2026-06-01 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms Ablation Therapy, Biospecimen Collection, Computed Tomography - Pancreatic Cystic Neoplasm | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2026-05-12 | 2026-05-29 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-14 |
| Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel. - Esophageal Cancer | Completed | Sichuan University | 387 | 2026-04-01 | 2026-08-24 | |
| ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma ONT01, Gemcitabine, Nab paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 61 | 2026-03-25 | 2026-05-19 |
Showing 20 of 589. Sign in to see all of them.
Breast Neoplasms (96) · Pancreatic Neoplasms (84) · Carcinoma, Non-Small-Cell Lung (80) · Ovarian Neoplasms (52) · Fallopian Tube Neoplasms (48) · Triple Negative Breast Neoplasms (42) · Lung Neoplasms (32) · Neoplasm Metastasis (27) · Squamous Cell Carcinoma of Head and Neck (23) · Neoplasms (19) · Breast Neoplasms, Male (18) · Endometrial Neoplasms (17) · Brenner Tumor (16) · Esophageal Neoplasms (16) · Melanoma (16)
National Cancer Institute (NCI) (125) · M.D. Anderson Cancer Center (39) · Gynecologic Oncology Group (15) · Fudan University (14) · Mayo Clinic (14) · University of Washington (14) · City of Hope Medical Center (12) · NRG Oncology (9) · Emory University (8) · Ohio State University Comprehensive Cancer Center (8) · SWOG Cancer Research Network (8) · Alliance for Clinical Trials in Oncology (7) · OHSU Knight Cancer Institute (7) · GOG Foundation (6) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (6)
United States (433) · China (104) · Canada (32) · South Korea (26) · Puerto Rico (22) · Spain (20) · Australia (18) · France (16) · Italy (14) · Japan (14) · Germany (11) · Taiwan (8) · United Kingdom (7) · Belgium (6) · Singapore (6)
Floor Backes, MD (4) · Clinton Yam (3) · Erkut Borazanci, MD (3) · Steven H Lin (3) · Suresh Ramalingam (3) · Amanda N Fader (2) · Bradley Monk (2) · Cathy Eng (2) · Charles D Lopez (2) · Charles Loprinzi (2) · Charles Shapiro (2) · David M Gershenson (2)
PMID 37185961, PMID 30998813, PMID 11698646, PMID 15030777, PMID 15240681, PMID 15358536, PMID 15771580, PMID 15800326, PMID 16227604, PMID 16236738, PMID 16277889, PMID 17167137, PMID 18235124, PMID 18565862, PMID 19087987, PMID 19426218, PMID 19706807, PMID 19738452, PMID 19877111, PMID 19931137, PMID 20516428, PMID 20530281, PMID 20625120, PMID 20636820, PMID 20658263, PMID 20837357, PMID 21359953, PMID 21461889, PMID 21472717, PMID 21502559, PMID 21941283, PMID 22042958, PMID 22200869, PMID 22204724, PMID 22307213, PMID 22915053, PMID 23219660, PMID 23248256, PMID 23969788, PMID 24013936, PMID 24068539, PMID 24239210, PMID 24327518, PMID 24422706, PMID 24552320, PMID 24779680, PMID 25092775, PMID 25332249, PMID 25476537, PMID 25492923
U10CA180868 (52), U10CA027469 (36), U10CA180820 (16), U10CA180888 (13), U10CA021661 (10), U10CA031946 (10), U10CA021115 (9), U10CA180821 (9), P30CA013330 (8), P30CA015083 (7), P30CA033572 (6), P30CA138292 (6), U01CA076576 (6), U01CA099168 (6), N01CM62201 (5)